Global Active Pharmaceutical Ingredients (API) CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Active Pharmaceutical Ingredients (API) CDMO market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Active Pharmaceutical Ingredients (API) CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Active Pharmaceutical Ingredients (API) CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Active Pharmaceutical Ingredients (API) CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Recipharm, Cambrex Corporation, Patheon (Thermo Fisher Scientific), CordenPharma and Lonza, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Active Pharmaceutical Ingredients (API) CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Active Pharmaceutical Ingredients (API) CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Active Pharmaceutical Ingredients (API) CDMO, with revenue, gross margin and global market share of Active Pharmaceutical Ingredients (API) CDMO from 2018 to 2023.
Chapter 3, the Active Pharmaceutical Ingredients (API) CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Active Pharmaceutical Ingredients (API) CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Active Pharmaceutical Ingredients (API) CDMO.
Chapter 13, to describe Active Pharmaceutical Ingredients (API) CDMO research findings and conclusion.
This report is a detailed and comprehensive analysis for global Active Pharmaceutical Ingredients (API) CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Active Pharmaceutical Ingredients (API) CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Active Pharmaceutical Ingredients (API) CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Recipharm, Cambrex Corporation, Patheon (Thermo Fisher Scientific), CordenPharma and Lonza, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Active Pharmaceutical Ingredients (API) CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Macromolecular API
- Small Molecule API
- Clinical
- Commercial
- Others
- Recipharm
- Cambrex Corporation
- Patheon (Thermo Fisher Scientific)
- CordenPharma
- Lonza
- Siegfried
- Catalent
- Boehringer Ingelheim
- Piramal Group
- AbbVie
- SGS Quay Pharmaceuticals
- Aenova Group
- Curia
- Sterling Pharma Solutions
- Eurofins CDMO
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Active Pharmaceutical Ingredients (API) CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Active Pharmaceutical Ingredients (API) CDMO, with revenue, gross margin and global market share of Active Pharmaceutical Ingredients (API) CDMO from 2018 to 2023.
Chapter 3, the Active Pharmaceutical Ingredients (API) CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Active Pharmaceutical Ingredients (API) CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Active Pharmaceutical Ingredients (API) CDMO.
Chapter 13, to describe Active Pharmaceutical Ingredients (API) CDMO research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Active Pharmaceutical Ingredients (API) CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Active Pharmaceutical Ingredients (API) CDMO by Type
1.3.1 Overview: Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type in 2022
1.3.3 Macromolecular API
1.3.4 Small Molecule API
1.4 Global Active Pharmaceutical Ingredients (API) CDMO Market by Application
1.4.1 Overview: Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinical
1.4.3 Commercial
1.4.4 Others
1.5 Global Active Pharmaceutical Ingredients (API) CDMO Market Size & Forecast
1.6 Global Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast by Region
1.6.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region, (2018-2029)
1.6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.4 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.6 South America Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Recipharm
2.1.1 Recipharm Details
2.1.2 Recipharm Major Business
2.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.1.4 Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Recipharm Recent Developments and Future Plans
2.2 Cambrex Corporation
2.2.1 Cambrex Corporation Details
2.2.2 Cambrex Corporation Major Business
2.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.2.4 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Cambrex Corporation Recent Developments and Future Plans
2.3 Patheon (Thermo Fisher Scientific)
2.3.1 Patheon (Thermo Fisher Scientific) Details
2.3.2 Patheon (Thermo Fisher Scientific) Major Business
2.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.3.4 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Patheon (Thermo Fisher Scientific) Recent Developments and Future Plans
2.4 CordenPharma
2.4.1 CordenPharma Details
2.4.2 CordenPharma Major Business
2.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.4.4 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 CordenPharma Recent Developments and Future Plans
2.5 Lonza
2.5.1 Lonza Details
2.5.2 Lonza Major Business
2.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.5.4 Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Lonza Recent Developments and Future Plans
2.6 Siegfried
2.6.1 Siegfried Details
2.6.2 Siegfried Major Business
2.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.6.4 Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Siegfried Recent Developments and Future Plans
2.7 Catalent
2.7.1 Catalent Details
2.7.2 Catalent Major Business
2.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.7.4 Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Catalent Recent Developments and Future Plans
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business
2.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.8.4 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Boehringer Ingelheim Recent Developments and Future Plans
2.9 Piramal Group
2.9.1 Piramal Group Details
2.9.2 Piramal Group Major Business
2.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.9.4 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Piramal Group Recent Developments and Future Plans
2.10 AbbVie
2.10.1 AbbVie Details
2.10.2 AbbVie Major Business
2.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.10.4 AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 AbbVie Recent Developments and Future Plans
2.11 SGS Quay Pharmaceuticals
2.11.1 SGS Quay Pharmaceuticals Details
2.11.2 SGS Quay Pharmaceuticals Major Business
2.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.11.4 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 SGS Quay Pharmaceuticals Recent Developments and Future Plans
2.12 Aenova Group
2.12.1 Aenova Group Details
2.12.2 Aenova Group Major Business
2.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.12.4 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Aenova Group Recent Developments and Future Plans
2.13 Curia
2.13.1 Curia Details
2.13.2 Curia Major Business
2.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.13.4 Curia Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Curia Recent Developments and Future Plans
2.14 Sterling Pharma Solutions
2.14.1 Sterling Pharma Solutions Details
2.14.2 Sterling Pharma Solutions Major Business
2.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.14.4 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Sterling Pharma Solutions Recent Developments and Future Plans
2.15 Eurofins CDMO
2.15.1 Eurofins CDMO Details
2.15.2 Eurofins CDMO Major Business
2.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.15.4 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Eurofins CDMO Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Active Pharmaceutical Ingredients (API) CDMO Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Active Pharmaceutical Ingredients (API) CDMO by Company Revenue
3.2.2 Top 3 Active Pharmaceutical Ingredients (API) CDMO Players Market Share in 2022
3.2.3 Top 6 Active Pharmaceutical Ingredients (API) CDMO Players Market Share in 2022
3.3 Active Pharmaceutical Ingredients (API) CDMO Market: Overall Company Footprint Analysis
3.3.1 Active Pharmaceutical Ingredients (API) CDMO Market: Region Footprint
3.3.2 Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Type Footprint
3.3.3 Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value and Market Share by Type (2018-2023)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2023)
5.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
6.2 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
6.3.1 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
6.3.2 United States Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
6.3.3 Canada Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
6.3.4 Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
7.3.1 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
7.3.2 Germany Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.3 France Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.5 Russia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.6 Italy Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region
8.3.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2018-2029)
8.3.2 China Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.3 Japan Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.4 South Korea Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.5 India Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.7 Australia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
9.2 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
9.3 South America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
9.3.1 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
9.3.2 Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
9.3.3 Argentina Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
10.3.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
10.3.2 Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
10.3.4 UAE Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Active Pharmaceutical Ingredients (API) CDMO Market Drivers
11.2 Active Pharmaceutical Ingredients (API) CDMO Market Restraints
11.3 Active Pharmaceutical Ingredients (API) CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Active Pharmaceutical Ingredients (API) CDMO Industry Chain
12.2 Active Pharmaceutical Ingredients (API) CDMO Upstream Analysis
12.3 Active Pharmaceutical Ingredients (API) CDMO Midstream Analysis
12.4 Active Pharmaceutical Ingredients (API) CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Active Pharmaceutical Ingredients (API) CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Active Pharmaceutical Ingredients (API) CDMO by Type
1.3.1 Overview: Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type in 2022
1.3.3 Macromolecular API
1.3.4 Small Molecule API
1.4 Global Active Pharmaceutical Ingredients (API) CDMO Market by Application
1.4.1 Overview: Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinical
1.4.3 Commercial
1.4.4 Others
1.5 Global Active Pharmaceutical Ingredients (API) CDMO Market Size & Forecast
1.6 Global Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast by Region
1.6.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region, (2018-2029)
1.6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.4 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.6 South America Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Recipharm
2.1.1 Recipharm Details
2.1.2 Recipharm Major Business
2.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.1.4 Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Recipharm Recent Developments and Future Plans
2.2 Cambrex Corporation
2.2.1 Cambrex Corporation Details
2.2.2 Cambrex Corporation Major Business
2.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.2.4 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Cambrex Corporation Recent Developments and Future Plans
2.3 Patheon (Thermo Fisher Scientific)
2.3.1 Patheon (Thermo Fisher Scientific) Details
2.3.2 Patheon (Thermo Fisher Scientific) Major Business
2.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.3.4 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Patheon (Thermo Fisher Scientific) Recent Developments and Future Plans
2.4 CordenPharma
2.4.1 CordenPharma Details
2.4.2 CordenPharma Major Business
2.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.4.4 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 CordenPharma Recent Developments and Future Plans
2.5 Lonza
2.5.1 Lonza Details
2.5.2 Lonza Major Business
2.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.5.4 Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Lonza Recent Developments and Future Plans
2.6 Siegfried
2.6.1 Siegfried Details
2.6.2 Siegfried Major Business
2.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.6.4 Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Siegfried Recent Developments and Future Plans
2.7 Catalent
2.7.1 Catalent Details
2.7.2 Catalent Major Business
2.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.7.4 Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Catalent Recent Developments and Future Plans
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business
2.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.8.4 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Boehringer Ingelheim Recent Developments and Future Plans
2.9 Piramal Group
2.9.1 Piramal Group Details
2.9.2 Piramal Group Major Business
2.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.9.4 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Piramal Group Recent Developments and Future Plans
2.10 AbbVie
2.10.1 AbbVie Details
2.10.2 AbbVie Major Business
2.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.10.4 AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 AbbVie Recent Developments and Future Plans
2.11 SGS Quay Pharmaceuticals
2.11.1 SGS Quay Pharmaceuticals Details
2.11.2 SGS Quay Pharmaceuticals Major Business
2.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.11.4 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 SGS Quay Pharmaceuticals Recent Developments and Future Plans
2.12 Aenova Group
2.12.1 Aenova Group Details
2.12.2 Aenova Group Major Business
2.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.12.4 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Aenova Group Recent Developments and Future Plans
2.13 Curia
2.13.1 Curia Details
2.13.2 Curia Major Business
2.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.13.4 Curia Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Curia Recent Developments and Future Plans
2.14 Sterling Pharma Solutions
2.14.1 Sterling Pharma Solutions Details
2.14.2 Sterling Pharma Solutions Major Business
2.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.14.4 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Sterling Pharma Solutions Recent Developments and Future Plans
2.15 Eurofins CDMO
2.15.1 Eurofins CDMO Details
2.15.2 Eurofins CDMO Major Business
2.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
2.15.4 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Eurofins CDMO Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Active Pharmaceutical Ingredients (API) CDMO Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Active Pharmaceutical Ingredients (API) CDMO by Company Revenue
3.2.2 Top 3 Active Pharmaceutical Ingredients (API) CDMO Players Market Share in 2022
3.2.3 Top 6 Active Pharmaceutical Ingredients (API) CDMO Players Market Share in 2022
3.3 Active Pharmaceutical Ingredients (API) CDMO Market: Overall Company Footprint Analysis
3.3.1 Active Pharmaceutical Ingredients (API) CDMO Market: Region Footprint
3.3.2 Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Type Footprint
3.3.3 Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value and Market Share by Type (2018-2023)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2023)
5.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
6.2 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
6.3.1 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
6.3.2 United States Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
6.3.3 Canada Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
6.3.4 Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
7.3.1 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
7.3.2 Germany Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.3 France Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.5 Russia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
7.3.6 Italy Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region
8.3.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2018-2029)
8.3.2 China Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.3 Japan Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.4 South Korea Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.5 India Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
8.3.7 Australia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
9.2 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
9.3 South America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
9.3.1 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
9.3.2 Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
9.3.3 Argentina Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
10.3.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
10.3.2 Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
10.3.4 UAE Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Active Pharmaceutical Ingredients (API) CDMO Market Drivers
11.2 Active Pharmaceutical Ingredients (API) CDMO Market Restraints
11.3 Active Pharmaceutical Ingredients (API) CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Active Pharmaceutical Ingredients (API) CDMO Industry Chain
12.2 Active Pharmaceutical Ingredients (API) CDMO Upstream Analysis
12.3 Active Pharmaceutical Ingredients (API) CDMO Midstream Analysis
12.4 Active Pharmaceutical Ingredients (API) CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Recipharm Company Information, Head Office, and Major Competitors
Table 6. Recipharm Major Business
Table 7. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 8. Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Recipharm Recent Developments and Future Plans
Table 10. Cambrex Corporation Company Information, Head Office, and Major Competitors
Table 11. Cambrex Corporation Major Business
Table 12. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 13. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Cambrex Corporation Recent Developments and Future Plans
Table 15. Patheon (Thermo Fisher Scientific) Company Information, Head Office, and Major Competitors
Table 16. Patheon (Thermo Fisher Scientific) Major Business
Table 17. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 18. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Patheon (Thermo Fisher Scientific) Recent Developments and Future Plans
Table 20. CordenPharma Company Information, Head Office, and Major Competitors
Table 21. CordenPharma Major Business
Table 22. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 23. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. CordenPharma Recent Developments and Future Plans
Table 25. Lonza Company Information, Head Office, and Major Competitors
Table 26. Lonza Major Business
Table 27. Lonza Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 28. Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Lonza Recent Developments and Future Plans
Table 30. Siegfried Company Information, Head Office, and Major Competitors
Table 31. Siegfried Major Business
Table 32. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 33. Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Siegfried Recent Developments and Future Plans
Table 35. Catalent Company Information, Head Office, and Major Competitors
Table 36. Catalent Major Business
Table 37. Catalent Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 38. Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Catalent Recent Developments and Future Plans
Table 40. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 41. Boehringer Ingelheim Major Business
Table 42. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 43. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Boehringer Ingelheim Recent Developments and Future Plans
Table 45. Piramal Group Company Information, Head Office, and Major Competitors
Table 46. Piramal Group Major Business
Table 47. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 48. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Piramal Group Recent Developments and Future Plans
Table 50. AbbVie Company Information, Head Office, and Major Competitors
Table 51. AbbVie Major Business
Table 52. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 53. AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. AbbVie Recent Developments and Future Plans
Table 55. SGS Quay Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 56. SGS Quay Pharmaceuticals Major Business
Table 57. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 58. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. SGS Quay Pharmaceuticals Recent Developments and Future Plans
Table 60. Aenova Group Company Information, Head Office, and Major Competitors
Table 61. Aenova Group Major Business
Table 62. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 63. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Aenova Group Recent Developments and Future Plans
Table 65. Curia Company Information, Head Office, and Major Competitors
Table 66. Curia Major Business
Table 67. Curia Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 68. Curia Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Curia Recent Developments and Future Plans
Table 70. Sterling Pharma Solutions Company Information, Head Office, and Major Competitors
Table 71. Sterling Pharma Solutions Major Business
Table 72. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 73. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Sterling Pharma Solutions Recent Developments and Future Plans
Table 75. Eurofins CDMO Company Information, Head Office, and Major Competitors
Table 76. Eurofins CDMO Major Business
Table 77. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 78. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Eurofins CDMO Recent Developments and Future Plans
Table 80. Global Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million) by Players (2018-2023)
Table 81. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Players (2018-2023)
Table 82. Breakdown of Active Pharmaceutical Ingredients (API) CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Active Pharmaceutical Ingredients (API) CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Active Pharmaceutical Ingredients (API) CDMO Players
Table 85. Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Type Footprint
Table 86. Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Application Footprint
Table 87. Active Pharmaceutical Ingredients (API) CDMO New Market Entrants and Barriers to Market Entry
Table 88. Active Pharmaceutical Ingredients (API) CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Share by Type (2018-2023)
Table 91. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Forecast by Type (2024-2029)
Table 92. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023)
Table 93. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Forecast by Application (2024-2029)
Table 94. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Active Pharmaceutical Ingredients (API) CDMO Raw Material
Table 125. Key Suppliers of Active Pharmaceutical Ingredients (API) CDMO Raw Materials
Table 1. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Recipharm Company Information, Head Office, and Major Competitors
Table 6. Recipharm Major Business
Table 7. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 8. Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Recipharm Recent Developments and Future Plans
Table 10. Cambrex Corporation Company Information, Head Office, and Major Competitors
Table 11. Cambrex Corporation Major Business
Table 12. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 13. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Cambrex Corporation Recent Developments and Future Plans
Table 15. Patheon (Thermo Fisher Scientific) Company Information, Head Office, and Major Competitors
Table 16. Patheon (Thermo Fisher Scientific) Major Business
Table 17. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 18. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Patheon (Thermo Fisher Scientific) Recent Developments and Future Plans
Table 20. CordenPharma Company Information, Head Office, and Major Competitors
Table 21. CordenPharma Major Business
Table 22. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 23. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. CordenPharma Recent Developments and Future Plans
Table 25. Lonza Company Information, Head Office, and Major Competitors
Table 26. Lonza Major Business
Table 27. Lonza Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 28. Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Lonza Recent Developments and Future Plans
Table 30. Siegfried Company Information, Head Office, and Major Competitors
Table 31. Siegfried Major Business
Table 32. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 33. Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Siegfried Recent Developments and Future Plans
Table 35. Catalent Company Information, Head Office, and Major Competitors
Table 36. Catalent Major Business
Table 37. Catalent Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 38. Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Catalent Recent Developments and Future Plans
Table 40. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 41. Boehringer Ingelheim Major Business
Table 42. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 43. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Boehringer Ingelheim Recent Developments and Future Plans
Table 45. Piramal Group Company Information, Head Office, and Major Competitors
Table 46. Piramal Group Major Business
Table 47. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 48. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Piramal Group Recent Developments and Future Plans
Table 50. AbbVie Company Information, Head Office, and Major Competitors
Table 51. AbbVie Major Business
Table 52. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 53. AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. AbbVie Recent Developments and Future Plans
Table 55. SGS Quay Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 56. SGS Quay Pharmaceuticals Major Business
Table 57. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 58. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. SGS Quay Pharmaceuticals Recent Developments and Future Plans
Table 60. Aenova Group Company Information, Head Office, and Major Competitors
Table 61. Aenova Group Major Business
Table 62. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 63. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Aenova Group Recent Developments and Future Plans
Table 65. Curia Company Information, Head Office, and Major Competitors
Table 66. Curia Major Business
Table 67. Curia Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 68. Curia Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Curia Recent Developments and Future Plans
Table 70. Sterling Pharma Solutions Company Information, Head Office, and Major Competitors
Table 71. Sterling Pharma Solutions Major Business
Table 72. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 73. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Sterling Pharma Solutions Recent Developments and Future Plans
Table 75. Eurofins CDMO Company Information, Head Office, and Major Competitors
Table 76. Eurofins CDMO Major Business
Table 77. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
Table 78. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Eurofins CDMO Recent Developments and Future Plans
Table 80. Global Active Pharmaceutical Ingredients (API) CDMO Revenue (USD Million) by Players (2018-2023)
Table 81. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Players (2018-2023)
Table 82. Breakdown of Active Pharmaceutical Ingredients (API) CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Active Pharmaceutical Ingredients (API) CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Active Pharmaceutical Ingredients (API) CDMO Players
Table 85. Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Type Footprint
Table 86. Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Application Footprint
Table 87. Active Pharmaceutical Ingredients (API) CDMO New Market Entrants and Barriers to Market Entry
Table 88. Active Pharmaceutical Ingredients (API) CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Share by Type (2018-2023)
Table 91. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Forecast by Type (2024-2029)
Table 92. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023)
Table 93. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Forecast by Application (2024-2029)
Table 94. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Active Pharmaceutical Ingredients (API) CDMO Raw Material
Table 125. Key Suppliers of Active Pharmaceutical Ingredients (API) CDMO Raw Materials
LIST OF FIGURES
s
Figure 1. Active Pharmaceutical Ingredients (API) CDMO Picture
Figure 2. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type in 2022
Figure 4. Macromolecular API
Figure 5. Small Molecule API
Figure 6. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application in 2022
Figure 8. Clinical Picture
Figure 9. Commercial Picture
Figure 10. Others Picture
Figure 11. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Active Pharmaceutical Ingredients (API) CDMO Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Region in 2022
Figure 16. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Players in 2022
Figure 22. Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Active Pharmaceutical Ingredients (API) CDMO Market Share in 2022
Figure 24. Global Top 6 Players Active Pharmaceutical Ingredients (API) CDMO Market Share in 2022
Figure 25. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Share by Type (2018-2023)
Figure 26. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Type (2024-2029)
Figure 27. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Share by Application (2018-2023)
Figure 28. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Application (2024-2029)
Figure 29. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 39. France Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Region (2018-2029)
Figure 46. China Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 49. India Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 63. Active Pharmaceutical Ingredients (API) CDMO Market Drivers
Figure 64. Active Pharmaceutical Ingredients (API) CDMO Market Restraints
Figure 65. Active Pharmaceutical Ingredients (API) CDMO Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Active Pharmaceutical Ingredients (API) CDMO in 2022
Figure 68. Manufacturing Process Analysis of Active Pharmaceutical Ingredients (API) CDMO
Figure 69. Active Pharmaceutical Ingredients (API) CDMO Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
s
Figure 1. Active Pharmaceutical Ingredients (API) CDMO Picture
Figure 2. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type in 2022
Figure 4. Macromolecular API
Figure 5. Small Molecule API
Figure 6. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application in 2022
Figure 8. Clinical Picture
Figure 9. Commercial Picture
Figure 10. Others Picture
Figure 11. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Active Pharmaceutical Ingredients (API) CDMO Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Region in 2022
Figure 16. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Players in 2022
Figure 22. Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Active Pharmaceutical Ingredients (API) CDMO Market Share in 2022
Figure 24. Global Top 6 Players Active Pharmaceutical Ingredients (API) CDMO Market Share in 2022
Figure 25. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Share by Type (2018-2023)
Figure 26. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Type (2024-2029)
Figure 27. Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Share by Application (2018-2023)
Figure 28. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Application (2024-2029)
Figure 29. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 39. France Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Region (2018-2029)
Figure 46. China Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 49. India Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Active Pharmaceutical Ingredients (API) CDMO Consumption Value (2018-2029) & (USD Million)
Figure 63. Active Pharmaceutical Ingredients (API) CDMO Market Drivers
Figure 64. Active Pharmaceutical Ingredients (API) CDMO Market Restraints
Figure 65. Active Pharmaceutical Ingredients (API) CDMO Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Active Pharmaceutical Ingredients (API) CDMO in 2022
Figure 68. Manufacturing Process Analysis of Active Pharmaceutical Ingredients (API) CDMO
Figure 69. Active Pharmaceutical Ingredients (API) CDMO Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
